Cargando…

Improvement of Prostaglandin-Associated Periorbitopathy after Discontinuing Treatment

OBJECTIVES: To report that the periorbital changes induced by prostaglandin analogue (PGA) eye drops are partially reversible after discontinuing treatment. MATERIALS AND METHODS: Nine patients with prostaglandin-associated periorbitopathy seen in a referral oculoplastic practice were included in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Abalo-Lojo, Jose Manuel, Ferreiro, Pedro Vázquez, Asorey, Maria Knight, Colmenero, Aida Estévez, Gonzalez, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973213/
https://www.ncbi.nlm.nih.gov/pubmed/36847619
http://dx.doi.org/10.4274/tjo.galenos.2022.24365
_version_ 1784898476582109184
author Abalo-Lojo, Jose Manuel
Ferreiro, Pedro Vázquez
Asorey, Maria Knight
Colmenero, Aida Estévez
Gonzalez, Francisco
author_facet Abalo-Lojo, Jose Manuel
Ferreiro, Pedro Vázquez
Asorey, Maria Knight
Colmenero, Aida Estévez
Gonzalez, Francisco
author_sort Abalo-Lojo, Jose Manuel
collection PubMed
description OBJECTIVES: To report that the periorbital changes induced by prostaglandin analogue (PGA) eye drops are partially reversible after discontinuing treatment. MATERIALS AND METHODS: Nine patients with prostaglandin-associated periorbitopathy seen in a referral oculoplastic practice were included in this study, eight with unilateral glaucoma and one with bilateral open-angle glaucoma. All of them had been treated with topical PGA for at least one year, before the treatment was discontinued for cosmetic reasons. RESULTS: In all cases, there were evident periocular differences between the treated eye and the fellow eye, consisting mainly of deepening of the upper eyelid sulcus and eyelid fat pad reduction. One year after discontinuing the PGA eye drops, improvement of these features was observed. CONCLUSION: Clinicians and patients should be aware of the side effects of topical PGA therapy on periorbital tissues, and that these side effects can partially regress after discontinuation of the medication.
format Online
Article
Text
id pubmed-9973213
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-99732132023-03-01 Improvement of Prostaglandin-Associated Periorbitopathy after Discontinuing Treatment Abalo-Lojo, Jose Manuel Ferreiro, Pedro Vázquez Asorey, Maria Knight Colmenero, Aida Estévez Gonzalez, Francisco Turk J Ophthalmol Original Article OBJECTIVES: To report that the periorbital changes induced by prostaglandin analogue (PGA) eye drops are partially reversible after discontinuing treatment. MATERIALS AND METHODS: Nine patients with prostaglandin-associated periorbitopathy seen in a referral oculoplastic practice were included in this study, eight with unilateral glaucoma and one with bilateral open-angle glaucoma. All of them had been treated with topical PGA for at least one year, before the treatment was discontinued for cosmetic reasons. RESULTS: In all cases, there were evident periocular differences between the treated eye and the fellow eye, consisting mainly of deepening of the upper eyelid sulcus and eyelid fat pad reduction. One year after discontinuing the PGA eye drops, improvement of these features was observed. CONCLUSION: Clinicians and patients should be aware of the side effects of topical PGA therapy on periorbital tissues, and that these side effects can partially regress after discontinuation of the medication. Galenos Publishing 2023-02 2023-02-24 /pmc/articles/PMC9973213/ /pubmed/36847619 http://dx.doi.org/10.4274/tjo.galenos.2022.24365 Text en © Copyright 2023 by Turkish Ophthalmological Association | Turkish Journal of Ophthalmology, published by Galenos Publishing House. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Abalo-Lojo, Jose Manuel
Ferreiro, Pedro Vázquez
Asorey, Maria Knight
Colmenero, Aida Estévez
Gonzalez, Francisco
Improvement of Prostaglandin-Associated Periorbitopathy after Discontinuing Treatment
title Improvement of Prostaglandin-Associated Periorbitopathy after Discontinuing Treatment
title_full Improvement of Prostaglandin-Associated Periorbitopathy after Discontinuing Treatment
title_fullStr Improvement of Prostaglandin-Associated Periorbitopathy after Discontinuing Treatment
title_full_unstemmed Improvement of Prostaglandin-Associated Periorbitopathy after Discontinuing Treatment
title_short Improvement of Prostaglandin-Associated Periorbitopathy after Discontinuing Treatment
title_sort improvement of prostaglandin-associated periorbitopathy after discontinuing treatment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973213/
https://www.ncbi.nlm.nih.gov/pubmed/36847619
http://dx.doi.org/10.4274/tjo.galenos.2022.24365
work_keys_str_mv AT abalolojojosemanuel improvementofprostaglandinassociatedperiorbitopathyafterdiscontinuingtreatment
AT ferreiropedrovazquez improvementofprostaglandinassociatedperiorbitopathyafterdiscontinuingtreatment
AT asoreymariaknight improvementofprostaglandinassociatedperiorbitopathyafterdiscontinuingtreatment
AT colmeneroaidaestevez improvementofprostaglandinassociatedperiorbitopathyafterdiscontinuingtreatment
AT gonzalezfrancisco improvementofprostaglandinassociatedperiorbitopathyafterdiscontinuingtreatment